We agree with Bergua et al.1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease.

Gozzetti, A., Fabbri, A., Lazzi, S., Bocchia, M., & Lauria, F. (2008). Reply to “Rituximab activity in CD20-positive multiple myeloma”. LEUKEMIA, 22, 1083-1084.

Reply to “Rituximab activity in CD20-positive multiple myeloma”

GOZZETTI, ALESSANDRO;FABBRI, ANNALISA;LAZZI, STEFANO;BOCCHIA, MONICA;LAURIA, FRANCESCO
2008

Abstract

We agree with Bergua et al.1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/29312
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo